Home » Advanced Oncotherapy (AVO) » Advanced Oncotherapy #AVO – Hardman & Co Research: Confidence greatly boosted

Advanced Oncotherapy #AVO – Hardman & Co Research: Confidence greatly boosted

Confidence greatly boosted: Advanced Oncotherapy (AVO) is focused on delivering a more affordable, novel, proton-based radiotherapy system, based on technology developed originally at the world-renowned CERN. Major technical milestones were achieved in 2017 and the company remains on track with its development plan. Confidence has been enhanced significantly with integration of the first three structures and overcoming the technical challenge of accelerating the proton beam. Meanwhile, construction of the Harley Street site is on schedule for completion in 1H 2018, and new financing and distribution arrangements add further to confidence about the whole project.

Please click here for the full report:


To contact us:

Hardman & Co
35 New Broad Street


Follow us on Twitter@HardmanandCo


Dr Martin Hall
Dr Dorothea Hill
Dr Gregoire Pave

+44 20 7194 7622


About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors’ understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies’ profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.

Leave a comment

I would like to receive Brand Communications updates and news...
Free Stock Updates & News
I agree to have my personal information transfered to MailChimp ( more information )
Join over 3.000 visitors who are receiving our newsletter and learn how to optimize your blog for search engines, find free traffic, and monetize your website.
We hate spam. Your email address will not be sold or shared with anyone else.